Home / Market News / $GILD
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Cantor Fitzgerald and Needham Update Gilead Sciences Ratings

Oct 30, 2026, 11:34 AM UTC · Primary ticker $GILD

Cantor Fitzgerald maintained an Overweight rating on Gilead Sciences and raised its price target to $175 from $155, while Needham reiterated a Buy rating with a $200 price target. These analyst actions follow Gilead's Q3 2026 earnings release, signaling positive sentiment regarding the company's financial performance and future prospects.

Following Gilead Sciences' third-quarter 2026 earnings, two prominent investment firms, Cantor Fitzgerald and Needham, updated their ratings and price targets. Cantor Fitzgerald maintained its 'Overweight' rating and increased its price target by $20 to $175, while Needham maintained its 'Buy' rating with a $200 price target. This indicates a positive outlook from these analysts on Gilead's recent financial performance and future growth trajectory. For traders, this could signal continued positive momentum for GILD stock in the short to medium term, as analyst upgrades often influence investor sentiment. The key opportunity lies in potential price appreciation driven by increased institutional interest, though the risk remains that the market may have already priced in these positive sentiments or that future earnings could disappoint.

$GILD positive Analyst rating upgrades/reaffirmations and price target increases
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.